// App-Quantinova.ai

7019 : Inotuzumab ozogamicin (IO) in combination with low-intensity chemotherapy as front-line therapy for older patients (pts) and as salvage therapy for adult with R/R acute lymphoblastic leukemia (ALL).

Researchers

Presenter

  • Elias Jabbour

Principal Investigators

  • Susan Mary O'Brien

  • Farhad Ravandi

  • Gautam Borthakur

  • Sergernne York

  • Rebecca Garris

  • Jorge E. Cortes

  • Hagop M. Kantarjian

  • Nitin Jain

  • Deborah A. Thomas

  • Guillermo Garcia-Manero

Medical Centers

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • MD Anderson Cancer Ctr, Houston, TXTGen, Phoenix, AZThe University of Texas MD Anderson Cancer Center, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Inotuzumab ozogamicin

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Methotrexate

  • Cytarabine liposomal

  • Rituximab

Outcome

  • Positive

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01371630

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved